Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Plug Power Inc (PLUG) Price & Performance

Neurocrine Biosciences IncTrade
Plug Power IncTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Plug Power Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Plug Power Inc trades at $1.75 (market cap $2.42B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.9× Plug Power Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Plug Power Inc for 41 Days on average.

NBIXPLUG
Market Cap
$14.36B$2.42B
Volume
1,237,18053,851,702
Sector
HealthIndustrials
52-Week High
$185.50$4.14
52-Week Low
$123.10$1.73
Typical Hold Time
23 Days41 Days
Enterprise Value
$14.37B$3.29B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.

The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.

Plug Power Inc

Plug Power (PLUG) trades at $1.78, down 4.3% today, with a bearish technical outlook and negative earnings momentum. The company continues to report significant losses with a net income margin of -220.59% and negative cash flow, though recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels. Analyst consensus shows mixed sentiment with 44.7% buy ratings and a $3.13 price target, representing 76% upside potential from current levels.

While PLUG shows potential through hydrogen infrastructure expansion and recent contract wins, the investment case remains high-risk due to persistent negative profitability, cash burn, and competitive pressures. The stock trades near analyst low targets, suggesting limited downside protection, making it suitable only for speculative investors comfortable with substantial volatility and execution risk in the clean energy sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NBIX

No sentiment data available yet.

PLUG
75% Buy25% Sell
Avg holding period · 41 Days

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX →

About Plug Power Inc

Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.

Read more on PLUG →